FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda
This article was originally published in The Pink Sheet Daily
Executive Summary
Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.
You may also be interested in...
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
King’s Dogged Pursuit of Alpharma Comes Up Aces
The combined specialty pharma company to be a leader in abuse-resistant pain meds.